Atypical parkinsonian syndromes (APS) may be found problematic due to overlapping clinical symptomatology, progressive course, lack of methods enabling accurate in vivo diagnosing and, at least so far, no disease modifying treatment available. Despite almost 100 years history, their exact pathogenetic mechanisms remain unknown. Growing interest in understanding pathogenesis of atypical parkinsonian syndromes, development of methods facilitating diagnostic process and clinical trials focused on possible therapies could be observed in last few years. Taking into account the magnitude of research done in this field recently, it is possible that the solution is at our fingertips.
The goal of this topic is to gather data considering most recent findings in the area of examination and treatment of atypical parkinsonian syndromes. It will serve as a basis to define the current state of knowledge concerning possibilities of performing accurate in vivo diagnosis, offering disease modifying therapy and will set the direction of development in this area for the next decades.
Thus, topic editors will welcome any types of manuscripts - research article, brief research article, review, and mini-review- about, but not limited to the following themes:
• Differential diagnosis of APS
• Pathogenesis and patomechanisms of neurodegeneration in atypical parkinsonian syndromes
• New diagnostic methods for APS
• Novelties in therapeutic approach to APS
• Potential drug action mechanisms in atypical parkinsonian syndromes
• Gene therapy in APS
Conflicts on interest: Dr. Florin Gandor is employed by Kliniken Beelitz GmbH and has previously received honoraria from Abbvie, Merz, BIAL, Stada. He served on advisory boards for Abbvie and receives royalties from Springer. None of the other Topic Editors have declared any conflicts of interest.
Atypical parkinsonian syndromes (APS) may be found problematic due to overlapping clinical symptomatology, progressive course, lack of methods enabling accurate in vivo diagnosing and, at least so far, no disease modifying treatment available. Despite almost 100 years history, their exact pathogenetic mechanisms remain unknown. Growing interest in understanding pathogenesis of atypical parkinsonian syndromes, development of methods facilitating diagnostic process and clinical trials focused on possible therapies could be observed in last few years. Taking into account the magnitude of research done in this field recently, it is possible that the solution is at our fingertips.
The goal of this topic is to gather data considering most recent findings in the area of examination and treatment of atypical parkinsonian syndromes. It will serve as a basis to define the current state of knowledge concerning possibilities of performing accurate in vivo diagnosis, offering disease modifying therapy and will set the direction of development in this area for the next decades.
Thus, topic editors will welcome any types of manuscripts - research article, brief research article, review, and mini-review- about, but not limited to the following themes:
• Differential diagnosis of APS
• Pathogenesis and patomechanisms of neurodegeneration in atypical parkinsonian syndromes
• New diagnostic methods for APS
• Novelties in therapeutic approach to APS
• Potential drug action mechanisms in atypical parkinsonian syndromes
• Gene therapy in APS
Conflicts on interest: Dr. Florin Gandor is employed by Kliniken Beelitz GmbH and has previously received honoraria from Abbvie, Merz, BIAL, Stada. He served on advisory boards for Abbvie and receives royalties from Springer. None of the other Topic Editors have declared any conflicts of interest.